REPL
Replimune Group, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +8.3% ·
share flow +17.7% ·
net new positions +7.7%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 75 | +2 | 45.55M | $503.98M | +13 | −11 |
| Q1 2026 | 75 | +4 | 41.32M | $315.89M | +10 | −6 |
| Q4 2025 | 71 | +3 | 45.45M | $441.76M | +3 | — |
| Q3 2025 | 15 | -4 | 32.26M | $135.16M | — | −4 |
| Q2 2025 | 16 | 0 | 29.86M | $277.39M | — | — |
| Q1 2025 | 13 | 0 | 20.78M | $202.64M | — | — |
| Q4 2024 | 13 | +1 | 19.63M | $237.78M | +2 | −1 |
| Q3 2024 | 11 | +1 | 14.48M | $158.71M | +1 | — |
| Q2 2024 | 10 | — | 16.01M | $144.07M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 10.96M | +11.0% | $132.76M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 10.96M | +11.0% | $132.76M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | State Street Global Advisors ✦ (passive) | 2.20M | — | $26.69M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.43M | +0.1% | $17.32M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.43M | +0.1% | $17.32M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Millennium Management ✦ | 1.19M | +3.0% | $14.41M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 1.10M | +352.5% | $13.28M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 1.10M | +352.5% | $13.28M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Wellington Management ✦ | 1.10M | +352.5% | $13.28M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Wellington Management ✦ | 1.10M | +352.5% | $13.28M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 972.58K | +12.1% | $11.78M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 972.58K | +12.1% | $11.78M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | Marshall Wace ✦ | 896.18K | New | $10.85M | 0.0% | New | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 896.18K | New | $10.85M | 0.0% | New | 1 | SEC ↗ |
| 15 | Marshall Wace ✦ | 896.18K | New | $10.85M | 0.0% | New | 1 | SEC ↗ |
| 16 | Point72 Asset Management ✦ | 283.97K | New | $3.44M | 0.0% | New | 1 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 212.59K | +18.6% | $2.57M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Renaissance Technologies ✦ | 156.94K | +45.7% | $1.90M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 136.36K | +0.4% | $1.65M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 20 | Citadel Advisors ✦ | 136.36K | +0.4% | $1.65M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 21 | Fisher Asset Management ✦ | 77.66K | 0.0% | $940,498 | 0.0% | Held | 3 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 15.31K | -44.9% | $185,393 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 15.31K | -44.9% | $185,393 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 15.31K | -44.9% | $185,393 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $10.85M | 0.0% |
| Marshall Wace | $10.85M | 0.0% |
| Marshall Wace | $10.85M | 0.0% |
| Point72 Asset Management | $3.44M | 0.0% |
Exited
| Norges Bank | $4.16M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 70.00K shares, $535 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 9.26K sh · $132,176
Officer · 11.45K sh · $148,481
Officer, Director · 39.34K sh · $510,253
Officer · 7.63K sh · $98,987
Officer · 11.45K sh · $148,468
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
11.8% of class · View original SEC filing ↗